Stromal cells influence cancer progression. Myofibroblasts are an important stromal cell type, which influence the tumour microenvironment by release of extracellular matrix (ECM) proteins, proteases, cytokines and chemokines. The mechanisms of secretion are poorly understood. Here, we describe the secretion of marker proteins in gastric cancer and control myofibroblasts in response to insulin-like growth factor (IGF) stimulation and, using functional genomic approaches, we identify proteins influencing the secretory response. IGF rapidly increased myofibroblast secretion of an ECM protein, TGFβig-h3. The secretory response was not blocked by inhibition of protein synthesis and was partially mediated by increased intracellular calcium (Ca 2+ ). The capacity for evoked secretion was associated with the presence of dense-core secretory vesicles and was lost in cells from patients with advanced gastric cancer. In cells responding to IGF-II, the expression of neuroendocrine marker proteins, including secretogranin-II and proenkephalin, was identified by gene array and LC-MS/MS respectively, and verified experimentally. The expression of proenkephalin was decreased in cancers from patients with advanced disease. Inhibition of secretogranin-II expression decreased the secretory response to IGF, and its over-expression recovered the secretory response consistent with a role in secretory vesicle biogenesis. We conclude that normal and some gastric cancer myofibroblasts have a neuroendocrine-like phenotype characterized by Ca 2+ -dependent regulated secretion, dense-core secretory vesicles and expression of neuroendocrine marker proteins; loss of the phenotype is associated with advanced cancer. A failure to regulate myofibroblast protein secretion may contribute to cancer progression.
Introduction
Myofibroblasts are stromal cells that play a role in regulating normal epithelial cell organization and function, determine wound healing, and increasingly are understood to influence cancer progression (1) (2) (3) . In many tissues, they are relatively rare, but in the gut they are normally well represented, where there is a population that forms a network closely allied to the epithelium. In cancer, however, myofibroblasts characteristically exhibit disordered architecture, morphology and function at least in part due to epigenetic changes (4) . They influence the tissue microenvironment by secretion of extracellular matrix (ECM) proteins, proteases and protease inhibitors, growth factors, cytokines and chemokines (5) . Recent work has indicated that secretion of the ECM adapter protein transforming growth factor-beta-inducible gene-h3 (TGFβig-h3; also known as βig-h3, TGFBI, βIGH3, keratoepithelin, MP78/70) is decreased in myofibroblasts from gastric cancers of patients with high lymph node involvement (6) . However, the mechanisms responsible for changes in myofibroblast protein secretion in cancer remain poorly understood.
Protein secretion in neurons, endocrine and exocrine cells occurs via either the constitutive pathway, where rates of release are determined by rates of synthesis, or the regulated pathway, where secretion occurs in response to acute stimulation via an increase in intracellular calcium (Ca 2+ ) leading to exocytosis of storage (usually dense cored) secretory vesicles (7) . In neurons and endocrine cells, the formation of dense-cored secretory vesicles at the trans-Golgi network occurs in response to aggregation of proteins including those of the chromogranin family that are often considered to be markers of a neuroendocrine phenotype (8) (9) (10) . In other cell types including stromal cells such as myofibroblasts, protein secretion is generally considered to be constitutive.
Insulin-like growth factors (IGF)-I and II are produced by gut myofibroblasts, stimulate proliferation and migration of both these and epithelial cells, and are associated with the pathogenesis of gastric cancer (11, 12) . In addition, they regulate protein secretion by myofibroblasts. In the present study, we hypothesized that differences in the secretory phenotype of different myofibroblasts were due to the presence or absence of a regulated exocytotic response to IGF. We report here that IGF stimulation of myofibroblasts results in acute release of a range of proteins from preformed secretory vesicles, that this property correlates with the expression of neuroendocrine markers and that it is lost in cancer-associated myofibroblasts (CAMs) from patients with high lymph node involvement.
Materials and methods

Myofibroblasts
Human primary CAMs and myofibroblasts from adjacent tissue to tumours (ATMs) were obtained from patients undergoing surgery for gastric cancer (Supplementary Table 1 , available at Carcinogenesis Online). These cells and the tissues from which they were obtained have previously been characterized (6, 13) . Normal tissue myofibroblasts (NTM) from healthy stomach were generated from deceased transplant donors with normal gastric histology. In all cases, cells (>99%) had been shown to be positive for α-smooth muscle actin and vimentin, and negative (>99%) for desmin and pancytokeratin. This work was approved by the Ethics Committee of the University of Szeged, Hungary. Myofibroblasts were cultured as described previously and were used between passages 3 and 10 (6).
Secretion assays
Cells (10 6 ) were plated in 10 cm dishes, incubated overnight, then washed three times with 10 ml sterile phosphate-buffered saline, incubated in 5 ml serum-free media for 1 h, followed by stimulation (30 min) with 100 ng ml −1 rhIGF-II (R&D Systems, Oxfordshire, UK), 50 ng ml −1 rh IGF-I (Calbiochem, Merck Biosciences, Beeston, UK), 2 µg ml −1 rhMMP-7 (Calbiochem) or 1 µM ionomycin (Sigma-Aldrich, Poole, UK). Preincubation for 30 min with 10 µg ml −1 brefeldin A (Epicentre Biotechnologies, Cambio Ltd, Cambridge, UK), 10 µg ml −1 cycloheximide (Sigma-Aldrich), 2 µg.ml
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Neuroendocrine phenotype of gastric myofibroblasts
was performed in some experiments. After stimulation, medium was centrifuged (800 g, 4°C, 7 min) and stored at −80°C.
Protein extraction
Medium was concentrated to a volume of about 100 µl using Amicon Ultra-15 3kDa centrifugal filter devices (Millipore, Watford, UK). Cellular protein was extracted using RIPA lysis buffer containing 1% vol/vol Phosphatase Inhibitor Cocktail set II, and 1% vol/vol Protease Inhibitor Cocktail Set III, EDTA-Free (Calbiochem). Cell extracts were stored at −80°C until further processed. Total protein was determined using the DC Protein Assay kit (Bio-Rad Lab, Hemel Hempstead, UK).
Western blots
Proteins were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, transferred to nitrocellulose (Amersham Pharmacia Biotech, Buckinghamshire, UK) and incubated with antibodies to TGFβig-h3, decorin, IGF-binding protein-5 (R&D Systems), tissue inhibitors of metalloproteinases-1, tissue inhibitors of metalloproteinases-2 (Chemicon, Chandlers Ford, UK), galectin-3 (Gal-3), lumican, secretogranin-II (SGII, Santa Cruz Biotechnology, Santa Cruz, CA) or plasminogen activator inhibitor-1 (GeneTex, Hsinchu City, Taiwan) followed by horseradish-peroxidase-conjugated secondary antibody and detection by incubation with SuperSignal® West Pico Chemiluminescent Substrate (Pierce, IL) and exposure to HyperFilm (Amersham Pharmacia Biotech). Samples of cell extracts were reprobed for glyceraldehyde 3-phosphate dehydrogenase (Biodesign, Saco, ME) to normalize for protein loading. Densitometric analysis of the band intensities from western blot analysis was performed using either ImageLab software v2.1 (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK) for the film-free developing method or Multi-Analyst v1.1 build 34 (Bio-Rad Lab) for films. The coefficient of variation of western blots of TGFβig-h3 was 6% (n = 6); based on this, differences of >1.2 in relative abundance between two samples run on the same gel were considered informative.
Intracellular Ca
2+
Intracellular [Ca 2+ ] was estimated using the Ca 2+ -sensitive fluorescent dye Fluo-4. Myofibroblasts (10 6 ) were plated on glass coverslips in six-well plates for 24 h and then loaded with Fluo-4 acetoxymethyl ester (Invitrogen, UK, 5 μM, dissolved in dimethyl sulphoxide with 0.1% pluronic F-127) for 60 min and then transferred to indicator-free solution for ≥30 min. Cells were continuously superfused at a rate of 5-6 ml min −1 and [Ca
] i measured using a confocal microscope (Ultraview, Perkin Elmer), connected to an iXon cooled charge-coupled device camera (Andor Technology, UK). Andor Technology iQ data acquisition software was used for data acquisition and analysis. Images were collected at 33 frames per second using a ×60 water objective (NA 1.20). Fluo-4 loaded cells were excited with the gas laser at a wavelength of 488 nm, and the fluorescence emission was measured at 510 nm.
Microarrays
Myofibroblasts (80% confluent) were extracted using RNeasy kits (Qiagen, Crawley, UK) according to the manufacturer's instructions. Samples were analysed using GeneChip©Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA) at the Liverpool Centre for Genomic Research according to the manufacturer's instructions using a GeneChip® Scanner 3000 (Affymetrix) (Supplementary Methods, available at Carcinogenesis Online). The data have been deposited at http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?acc=GSE44740. Further analysis was performed using MetaCore™ (GeneGo, www.genego.com) and gene products were annotated using Gene Ontology database (www.geneontology.org).
Stable isotope labelling by amino acids in cell culture and protein identification (SILAC)
Cells were cultured in media supplemented with either 12 C 6 lysine and 12 C 6 arginine (light label), or 13 C 6 lysine and 13 C 6 arginine (heavy label) for at least six population doublings. Myofibroblasts (10 6 cells, 10 cm diameter dishes) were then washed three times with phosphate-buffered saline and cultured in serum-free media for 1 h. Medium was discarded and replaced with 5 ml serum-free media with or without IGF-II (100 ng ml −1 ). After 30 min, medium was collected, centrifuged (800g, 7 min) and concentrated using StrataClean resin (Agilent Technologies, Wokingham, UK). Samples were processed in triplicate by a Nano-Acquity (Waters Ltd, Elstree, UK) reverse-phase high-performance liquid chromatography system in-line with an LTQ Orbitrap Velos (Thermo Scientific, Southend-on-Sea, UK). SILAC data were searched and analysed using MaxQuant 1.1.1.36 against the human IPI database v3.68 (14) . Proteins were reported based on the assignment of at least one tryptic peptide with a confidence >99% and a local false discovery rate calculated using the PSPEP (Proteomics Performance Evaluation Pipeline Software) algorithm of <1% (Supplementary Methods, available at Carcinogenesis Online).
Immunocytochemistry Cells (1 × 10 4 ) plated on four-well chamber slides (BD Falcon), or on cover slips in 24-well plates, were processed for immunocytochemistry using antibodies to TGFβig-h3 (Cell Signalling), decorin (R&D Systems), SGII, Gal-3, adrenomedullin, somatostatin, peptidyl α-amidating mono-oxygenase (all from Santa Cruz) and two fragments of proenkephalin, YGGFMRF (MetEnk-RF) and YGGFMRGL (MetEnk-RGL) (15, 16) , followed by conjugated secondary antibodies as appropriate. Formalin-fixed, paraffin-embedded, sections of tumours from which myofibroblasts had been prepared were processed for detection of proenkephalin products after antigen recovery using Multivision Polymer Detection System (Thermo Scientific) with assessment of the intensity of staining on a four-point (0-3) scale (6) . Slides were observed using a Zeiss Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City, UK), and images were taken using an Axiocam HRm camera (Zeiss) and processed by AxioVision 4.5 (Zeiss). Confocal microscopy was performed using Leica SP2 AOBS confocal microscope (Leica Microsystems, Milton Keynes, UK) and images processed by Leica confocal software (Leica Microsystems).
Transmission electron microscopy
Myofibroblasts (80% confluency in 10 cm dishes) were processed for transmission electron microscopy (TEM) using a resin pellet embedding protocol as published previously (17) . Multiple images were taken of 5-10 cells from four myofibroblast lines: two exhibiting and two lacking regulated secretion. The analysis of images for the presence of dense-core secretory vesicles was conducted by an observer who was blind to the identity of the cells. Size of the secretory vesicles was measured using AnalySIS Pro 3.2 (Build 678) program.
Protein knockdown and over-expression
Mission® Silencing RNAs (SASI_Hs01 00132008, SASI_Hs02 00335724 and SASI_Hs01 00132010) for SGII (Sigma-Aldrich) were re-suspended in 100 µl Tris/ethylenediaminetetraacetic acid buffer (100 µM). An expression vector encoding human SGII (10 µg, NM_003469.3) (OriGene Technologies, Rockville, MD) was reconstituted with 100 µl 5 mM Tris-HCl to give 0.1 µg ml −1 . Transfections, including scrambled RNA or empty vector pcDNA3 as controls, were performed using Amaxa Human Dermal Fibroblast Nucleofector kit (Lonza) on a Nucleofector® I device according to the manufacturer's instructions. Cells were then incubated for 96 h before secretion assays were performed and samples processed as described above.
Statistics
Results are expressed as mean ± standard error of the mean, unless otherwise stated. Student's t-test was used to determine statistical significance of results and considered significant at P < 0.05, unless otherwise stated. Further information on the statistical analysis of microarray and proteomic data is provided in the Supplementary Methods (available at Carcinogenesis Online).
Results
IGF-regulated exocytosis in gastric myofibroblasts
Basal release of TGFβig-h3 was characterized by bands of 68 and 74 kD that varied among myofibroblast samples (6) . In NTMs treated with IGF-II, there was typically a rapid increase in TGFβig-h3 secretion and similar results were obtained with IGF-I (Supplementary Figure 1 , available at Carcinogenesis Online). The secretory response did not depend on protein synthesis since it was maintained in the presence of cycloheximide and actinomycin D ( Figure 1A) . Interestingly, both of the latter reduced unstimulated secretion compatible with the existence of two secretory pathways: basal release via the constitutive route and dependent on synthesis of new protein, and IGF-II-evoked secretion from a preformed pool of storage vesicles. In keeping with this concept, disruption of Golgi trafficking and function using brefeldin A (BFA) also suppressed unstimulated secretion but did not inhibit the secretory response to IGF-II ( Figure 1B) . To address the question of whether endogenous IGF stimulated secretion, we made use of the fact that matrix metalloproteinase (MMP)-7 cleaves IGF-binding protein-5 released by myofibroblasts, thereby liberating IGF-II that has autocrine stimulatory effects on these cells (11, 18) . Consistent with a role for endogenous IGF-II in this system, we found that MMP-7 stimulated TGFβig-h3 secretion and that this was blocked by the MMP inhibitor, marimastat (Figure1C).
The secretory response to IGF-II was reduced by removal of extracellular Ca 2+ , whereas the Ca 2+ ionophore, ionomycin, increased secretion indicating Ca 2+ -dependent regulated exocytosis (Supplementary Figure 2 , available at Carcinogenesis Online). To explore the implication that IGF-II increases intracellular Ca 2+ to trigger exocytosis from the regulated secretory pathway, we performed imaging of Fluo-4 loaded myofibroblasts. Thus, 58 ± 5% of cells treated with IGF-II showed a prompt increase in intracellular Ca 2+ , which appeared as a slowly propagating Ca 2+ wave that was abolished by removal of Ca 2+ from the medium ( Figure 1D ). Similarly, MMP-7 (2μg ml −1 ) increased intracellular Ca 2+ , which was suppressed by removal of extracellular Ca 2+ ( Figure 1E ) and by neutralizing antibody to IGF-II (data not shown). The effect of MMP-7 was abolished by AG1024 consistent with actions via IGF-1R tyrosine kinase activity (Supplementary Figure 3 , available at Carcinogenesis Online).
Regulated secretion of TGFβig-h3 is lost in some CAMs
We then compared regulated exocytosis in a panel of NTMs, ATMs and CAMs recovered from a total of 22 patients. Stimulated secretion of TGFβig-h3 was found in 7 of 8 different NTMs (responders) and a high proportion (62.5%, 10 of 16) of ATMs, but interestingly only 43% of CAMs (6 of 14; Figure 2A ). There was no correlation between regulated secretion and patient age, distant metastases (M1 in only one patient) or degree of tumour differentiation (all G2 or G3). The nonresponder CAMs tended to have come from tumours with increased invasion (7 of 8 from T3 or T4 tumours) compared with responder CAMs (2 of 6 from T3 or T4 tumours) but this just failed to achieve statistical significance (P <0.06, Fisher exact test). However, when CAMs were divided into two groups based on lymph node involvement (pN0-1 versus pN2-4; patient survival 51 versus 12 months, respectively, P < 0.01), 75% of CAMs (6 of 8) from patients with low lymph node involvement were responders, and all six lines recovered from patients with high lymph node involvement were non-responders ( Figure 2B , P < 0.05, Fisher exact test). All ATMs from patients with responder CAMs were also responders, whereas 57% of ATMs (4 of 6) were responders from patients with non-responder CAMs. Because BFA inhibited basal secretion, we considered the possibility that it might unmask a small stimulated response that was obscured by high constitutive release; however, treatment with BFA of myofibroblasts that were apparent non-responders revealed diminished basal secretion but no stimulated TGFβig-h3 release ( Figure 2C ).
The regulated secretory pathway is associated with the presence of dense-cored, Golgi-derived secretory vesicles. Interestingly, therefore, we identified dense-cored secretory vesicles in the close vicinity of the Golgi complex in two different responder cell lines (mean diameter, 197.4 ± 10.3 nm, n = 17, from seven fields in six cells) ( Figure 2D ) using TEM. Typically, the electron-dense core occupied a relatively small proportion of the vesicle lumen. Similar vesicles were occasionally found scattered throughout the cytosol. In contrast, in two non-responder cell lines, dense-core vesicles of similar diameter were identified rarely in one (mean diameter, 202.5 ± 13.1 nm, n = 3, from 31 fields in 15 cells) and were undetectable in the other ( Figure 2E ). Rough endoplasmic reticulum and Golgi stacks were observed routinely in all cells whether they exhibit regulated exocytosis or not ( Figure 2D and E).
SGII is increased in myofibroblasts exhibiting regulated secretion
To gain insight into the differences between responder and nonresponder cells, we examined microarray data from the two cell types. For these purposes, the designation of responder and non-responder cells was made regardless of tissue origin, i.e. normal, adjacent or tumour tissue; the mean relative increase in TGFβig-h3 determined by western blot in response to IGF-II in responder cells was 3.2 ± 0.3 fold compared with 1.0 ± 0.02 in non-responder cells (Supplementary  Table 2 , available at Carcinogenesis Online). Of the identified transcripts encoding putative secretory proteins (Supplementary Table 3 , available at Carcinogenesis Online), the one exhibiting the greatest relative enrichment in responder cells was the neuroendocrine cell secretory marker, SGII (chromogranin C). Western blot analysis confirmed that cellular SGII abundance was higher in myofibroblasts from responder than non-responder cells ( Figure 3A and B) . Immunocytochemical studies revealed punctuate staining of SGII in responder cells, compatible with localization to secretory vesicles, and rare SGII-positive secretory vesicles in non-responder cells ( Figure 3C ). Moreover, in responder cells, there was stimulated exocytosis of SGII in response to IGF-II ( Figure 3D) . 
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Identification of the regulated secretome of gastric myofibroblasts
To define the range of proteins exhibiting regulated exocytosis, we then applied a proteomic approach to analyse the medium in SILAC labelled myofibroblasts treated with IGF-II. A total of 99 putative secretory proteins (Supplementary Table 4 and Figure 4 , available at Carcinogenesis Online) were identified. Using Perseus (MaxQuant), 61 secretory proteins exhibited statistically significantly higher abundance in response to IGF-II. The largest groups exhibiting regulated secretion were ECM and binding proteins, whereas immune system proteins were the largest group in samples exhibiting only constitutive secretion. Interestingly, further markers of a neuroendocrine phenotype including proenkephalin and adrenomedullin were also identified in the regulated secretome ( Figure 4A ; Supplementary Table 4 , available at Carcinogenesis Online); moreover, a search for putative neuroendocrine markers in the secretomes of other gastric myofibroblasts previously deposited in the PRIDE database (http://www.ebi.ac.uk/pride/, accession numbers 27157−27161) (19) confirmed the secretion of SGII, proenkephalin and adrenomedullin and further identified other putative markers including somatostatin and peptidyl α-amidating mono-oxygenase 
Neuroendocrine-like secretory vesicles in myofibroblasts
To validate putative neuroendocrine markers in myofibroblasts, we compared the cellular localization of proteins exhibiting regulated secretion or not. ECM proteins such as TGFβig-h3 and decorin that exhibited regulated secretion were localized to a common vesicular population ( Figure 5A ). Moreover, decorin was co-localized with a putative neuroendocrine marker proenkephalin ( Figure 5B ); proenkephalin and SGII were also found in a common vesicle population ( Figure 5C ). Immunohistochemical studies for other neuroendocrine markers including somatostatin, adrenomedullin and peptidyl α-amidating mono-oxygenase showed punctate staining and co-localization with SGII (peptidyl α-amidating mono-oxygenase, adrenomedullin) in responder CAMS consistent with localization to vesicles of the regulated secretory pathway (Supplementary Figure 5 , available at Carcinogenesis Online). In contrast, Gal-3 that did not exhibit regulated secretion was not co-localized at the vesicular level with the neuroendocrine marker SGII ( Figure 5D ).
To determine the in vivo relevance of myofibroblast expression of neuroendocrine markers, we then examined localization of a putative neuroendocrine marker (proenkephalin) in the tumours from which the myofibroblast had been prepared. There was localization compatible with nerve fibres and also staining of tumour cells. In addition, however, proenkephalin immunoreactivity was localized to myofibroblasts defined as stromal cells with stellate or spindle-like morphology that in parallel sections were α-smooth muscle actin positive ( Figure 5E ). The intensity of staining in myofibroblasts varied between tumours: in tumours giving rise to responder CAMs from patients with low lymph node involvement, the staining was significantly greater than in those with high lymph node involvement ( Figure 5F ).
Secretogranin-II is a determinant of myofibroblast-regulated secretion
To understand the mechanisms that might determine the capacity for regulated exocytosis, we explored the specific hypothesis that SGII plays a role in the biogenesis of dense-core secretory granules. We therefore examined release of TGFβig-h3 as an example of a protein exhibiting regulated secretion, and Gal-3 as an example of a constitutively secreted protein, after manipulating SGII expression. Thus, when cellular SGII in responder cells was reduced by 72% using small interfering RNA, (Supplementary Figure 6 , available at Carcinogenesis Online), there was inhibition of IGF-stimulated secretion of TGFβig-h3 but no change in Gal-3 secretion ( Figure 6A ). In contrast, when SGII was over-expressed in non-responder myofibroblasts by approximately 2-fold (Supplementary Figure 6 , available at Carcinogenesis Online), the stimulated secretion of TGFβig-h3 was restored but again there was no change in Gal-3 secretion ( Figure 6B ).
Discussion
Differences between tumour-derived and control myofibroblasts are increasingly recognized and there is growing evidence that they contribute to tumour progression (1, 20) . These cells are important regulators of the tissue microenvironment through release of ECM proteins, cytokines, chemokines, growth factors, proteases and protease inhibitors. However, the mechanisms regulating protein secretion from them have not been well studied. We report here that gastric myofibroblasts exhibit IGF-stimulated protein secretion through mechanisms consistent with exocytosis from preformed storage vesicles. Regulated exocytosis is a characteristic of neuroendocrine and exocrine cells, and the present study shows that several putative neuroendocrine markers including SGII, proenkephalin and somatostatin are expressed in myofibroblasts. Secretogranin-II plays a role in secretory vesicle formation and we find its knockdown reduced secretory responses to IGF. Interestingly, the capacity for stimulated secretion was lost in cells recovered from the tumours of patients with high lymph node involvement, was associated with depressed SGII abundance, and was at least partly restored by over-expression of SGII. The data suggest that myofibroblasts normally have the capacity to rapidly influence the tissue microenvironment through regulated exocytosis, but this phenotype is lost with cancer progression as a consequence of decreased ability to form secretory vesicles of the regulated pathway of exocytosis.
Gastric CAMs exhibit increased migration and proliferation in response to IGF stimulation compared with ATMs; conditioned media from them stimulates cancer cell proliferation and migration in vitro, and in xenografts they stimulate tumour growth (6) . Moreover, there appear to be differences between CAMs depending on cancer progression with increased proliferation and decreased secretion of TGFβig-h3 from patients with advanced disease (6); interestingly, knockdown of TGFβig-h3 in myofibroblasts increased migration in response to IGF-II and enhanced the activity of conditioned media in stimulating cancer cell migration. In the present study, we have investigated mechanisms of TGFβig-h3 secretion and unexpectedly found release via a neuroendocrine-like mechanism. Regulated secretion of proteins is associated with the biogenesis of Golgi-derived dense-cored vesicles, and TEM revealed this type of secretory vesicle in responder but not in non-responder cells, while Golgi complex and rough endoplasmic reticulum were similar in the two classes of cell. In addition to ECM proteins such as TGFβig-h3 and decorin, a diverse range of other secretory proteins including a neuroendocrine marker, SGII, was found to exhibit IGF-stimulated exocytosis. Nevertheless, not all secretory proteins exhibit IGF-stimulated exocytosis; one constitutively released protein, Gal-3, exhibited a cellular localization distinct from that of SGII, and in future experimental studies might provide a useful marker for constitutive secretion. As a whole, the data indicate that some myofibroblasts possess the capacity to segregate many, but not all, of their secretory proteins into vesicles that can be discharged in response to acute stimulation by IGF.
In stromal cells, such as myofibroblasts, the process of constitutive secretion has generally been thought to account for the release of secreted proteins. In contrast, regulated exocytosis is typically associated with neuronal, endocrine and exocrine cell secretion even though it has been clear for some time that it may also be a property of a wider spectrum of cell types (21) (22) (23) . In fibroblasts, Ca 2+ -dependent exocytosis has been described previously, notably in association with repair of the plasma membrane after damage (24) . In addition, Ca 2+ -and protein kinase C-stimulated secretion of glycosaminoglycans has been demonstrated in cells that are not usually associated with regulated secretion, such as L-cells and Chinese hamster ovary cells, and indeed analogous processes may account for insertion of GLUT4 into the plasma membrane in muscle cells (25) (26) (27) . Nevertheless, although the secretion of ECM proteins by myofibroblasts is well recognized, the mechanisms controlling the quantities of protein released have generally been assumed to occur at the transcriptional level (28) (29) (30) . The present data indicate that disruption of regulated exocytosis should now be considered in models of how stromal cells influence cancer progression.
Previous studies have reported increased intracellular Ca 2+ in response to IGF-I in a range of cell types including skeletal muscle, chondrocytes, thyroid cells and 3T3 fibroblasts (31) (32) (33) . These effects have been linked to the role of IGF-I in stimulating progression through the cell cycle (34) . The IGF-I receptor mediates the action of both IGF-I and IGF-II; the latter was used in the present studies because it is an endogenous autocrine growth factor for myofibroblasts; indeed we showed regulated exocytosis and increased intracellular Ca 2+ in response to MMP-7 that liberates endogenous IGF-II via cleavage of IGF-binding proteins (18) . Increased intracellular Ca 2+ is a primary determinant of regulated exocytosis and it would not be surprising that if in addition to IGF, other myofibroblast stimulants, particularly those acting via G-protein-coupled receptors to increase intracellular Ca 2+ , were also secretagogues. Secretory proteins destined for regulated exocytosis are segregated from those destined for constitutive release at the level of the transGolgi network. The packaging process is thought to involve aggregation into electron-dense cores of some proteins, notably those of the chromogranin family, in conditions of increased Ca 2+ and decreased pH that occur in the trans-Golgi network (10, 35, 36) . In this context, the discovery that a member of the chromogranin family, SGII, is expressed in myofibroblasts suggests a mechanism for the formation of regulated secretory vesicles. This was confirmed by demonstrating that inhibition of SGII expression depresses IGF-stimulated exocytosis. Moreover, deficits in regulated secretion and SGII expression in myofibroblasts recovered from patients with advanced gastric cancer were at least partially rescued by transfection with an SGII expression plasmid. In the future, it would be worthwhile examining quantitatively the relationship between SGII expression in myofibroblasts and the biogenesis of dense-cored secretory vesicles using TEM.
The concept that myofibroblasts exhibit a neuroendocrine-like phenotype is based on expression of neuroendocrine-related proteins, the presence of dense-cored secretory vesicles, and on the functional capacity to mount a prompt Ca 2+ -dependent secretory response on stimulation. It could be argued that the neuroendocrine-like phenotype reflects an adaptation of some myofibroblasts to tissue culture. It is important to note, therefore, we also found by immunocytochemistry the expression of proenkephalin in myofibroblasts in the original tumours from which the present cells were cultured; moreover, the expression of proenkephalin was decreased in tumours from patients with advanced gastric cancer, which correlates with the observation of loss of regulated exocytosis by these cells in culture. Mixed adenoneuroendocrine carcinomas in which a variable proportion of neuroendocrine cells are mixed with exocrine or glandular gastrointestinal cancer cells are well documented (37) . However, it is important to distinguish between the frank neuroendocrine phenotype in these cases (which is a property of cells of an epithelial lineage) and the neuroendocrine-like phenotype we describe in myofibroblasts. The latter phenotype probably includes expression of a more limited range of neuroendocrine markers, and for this reason, we refer to it as "neuroendocrine-like." Nevertheless, the suggestion that the phenotype changes in advanced disease as indicated by lymph node involvement and post-operative survival suggests that it would now be appropriate to perform formal, appropriately powered, studies to assess the value of neuroendocrine marker expression in myofibroblasts in the staging and prognosis of patients with gastric cancer. Since the phenotype also involves expression of potential regulatory peptides, the possible role of the latter in tumour progression should also be considered.
The present study has identified an unexpected contribution of IGF-stimulated secretion to the composition of the myofibroblast secretome. The data support a model by which myofibroblasts exposed to IGF are normally capable of rapidly secreting a range of proteins that acutely influence the cellular microenvironment, for example in tissue damage and wound healing. Loss of this property occurs in myofibroblasts in advanced cancer and is associated with loss of SGII expression and decreased biogenesis of storage vesicles. Manipulation of the mechanisms controlling storage vesicle biogenesis may, therefore, offer therapeutic benefits, as well as provide a novel marker of disease progression.
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